Philip Downing Net Worth

The estimated Net Worth of Philip A Downing is at least $424 Thousand dollars as of 10 June 2019. Mr. Downing owns over 5,000 units of Basis Global Technologies Inc stock worth over $423,577 and over the last 10 years he sold BASI stock worth over $0. In addition, he makes $0 as Vice President - Preclinical Services at Basis Global Technologies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Downing BASI stock SEC Form 4 insiders trading

Philip has made over 5 trades of the Basis Global Technologies Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of BASI stock worth $9,800 on 10 June 2019.

The largest trade he's ever made was exercising 10,000 units of Basis Global Technologies Inc stock on 1 March 2017 worth over $10,100. On average, Philip trades about 2,800 units every 137 days since 2015. As of 10 June 2019 he still owns at least 25,765 units of Basis Global Technologies Inc stock.

You can see the complete history of Mr. Downing stock trades at the bottom of the page.

Philip Downing biography

Philip A. Downing is Vice President - Preclinical Services of the company. Mr. Downing has extensive experience designing and testing pre-clinical dosing formulations and has achieved success in securing an extensive customer base for preclinical and clinical service needs. After receiving a B.A. in Chemistry and Biology from Indiana University, he worked for a clinical research facility, GFi Pharmaceuticals (now Covance Labs) as an Analytical Scientist and RSO designing and validating radiolabeled and non-radiolabeled assays used to support clinical ADME studies.

How old is Philip Downing?

Philip Downing is 45, he's been the Vice President - Preclinical Services of Basis Global Technologies Inc since 2015. There are 4 older and no younger executives at Basis Global Technologies Inc. The oldest executive at Basis Global Technologies Inc is Richard Johnson, 70, who is the Independent Director.

What's Philip Downing's mailing address?

Philip's mailing address filed with the SEC is C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE, IN, 47906.

Insiders trading at Basis Global Technologies Inc

Over the last 21 years, insiders at Basis Global Technologies Inc have traded over $266,443 worth of Basis Global Technologies Inc stock and bought 540,162 units worth $1,698,287 . The most active insiders traders include Jacqueline M Lemke, Robert Jr. Leasure, and William D Pitchford. On average, Basis Global Technologies Inc executives and independent directors trade stock every 65 days with the average trade being worth of $128,544. The most recent stock trade was executed by Beth Taylor on 5 March 2021, trading 5,000 units of BASI stock currently worth $88,500.

What does Basis Global Technologies Inc do?

Complete history of Mr. Downing stock trades at Basis Global Technologies Inc

Basis Global Technologies Inc executives and stock owners

Basis Global Technologies Inc executives and other stock owners filed with the SEC include:

• Wendy Perrow,
  Independent Director
• R. Matthew Neff,
  Independent Director
• Richard Johnson,
  Independent Director
• Joseph Flynn,
  Chief Commercial Officer
• John Sagartz,
  Chief Strategy Officer, Director
• Connie Dougherty,
  Vice President - Business Development
• I.M. Grossi,
  Vice President - Toxicology
• Philip Downing,
  Vice President - Preclinical Services
• Andrew Alexander,
  Vice President - Pharmacology and Toxicology Operations
• Michael Baim,
  Vice President - Bioanalytical Operations
• Beth Taylor,
  Chief Financial Officer, Vice President - Finance
• Robert Leasure,
  President, Chief Executive Officer, Director
• Gregory Davis,
  Interim Chairman of the Board
• Jill Blumhoff,
  VP, Finance & CFO
• John P Devine,
  VP--Toxicology
• James Sevall Bourdage,
  VP, Bioanalytical Services
• Jacqueline M Lemke,
  CFO & Vice President--Finance
• Jeffrey Potrzebowski,
  VP, Finance & CFO
• John Gregory Beattie,
  Chief Operating Officer
• Peterkissinger Candice B Ki...,
  
• Daniel Thomas Oakley,
  Chief Operating Officer
• Kimberly L Sagartz,
  10% owner
• Chrysalis, Llc Sw,
  10% owner
• Lori Payne,
  VP Bioanalytical Services
• Larry Steven Boulet,
  Director
• David W Crabb,
  Director
• John B. Landis,
  Director
• David L Omachinski,
  Director
• Anthony S Chilton,
  COO, Scientific Studies
• A. Charlene Sullivan,
  Director
• Alberto F Jr Hidalgo,
  VP, Bus. Development & Mrkting
• Leslie B Daniels,
  Director
• Kathleen Hodges,
  Vice President of Quality
• Lina L Reeves Kerner,
  V.P. - Human Resources
• Richard M Shepperd,
  President & Chief Exec. Off.
• Ronald E Shoup,
  Chief Operating Officer
• Craig S Bruntlett,
  Sr. V.P. International Sales
• Jon Brewer,
  VP Sales/Marketing
• William E Baitinger,
  Director
• Candice B Kissinger,
  Vice President
• Margaret B Mcclure,
  Dir, Pharmaceutical Lab. Div.
• Michael R Cox,
  V.P. Finance, CFO
• Emilio Cordova,
  V.P. of Business Development
• Edward Chait,
  Executive Vice President
• Gerry Henningsen,
  Director BAS Evansville
• Donnie A Evans,
  Vice President Engineering
• Garyl W Doster,
  Director
• Michael P Silvon,
  Vice President
• Michael S Noone,
  Dir. of Clinical Affairs, Balt
• William Sawyers,
  Laboratory Director
• William D Pitchford,
  Chief HR Officer